BACKGROUND: Hypertension-induced left ventricular hypertrophy (LVH) is associated with an increased risk of cardiovascular morbidity and death by mechanisms not well characterized. METHODS AND RESULTS: Myocardial fatty acid (FA) metabolism and left ventricular (LV) mass were evaluated in 13 patients with hypertensive LVH with normal LV ejection fraction and 42 normal control subjects (primary cohort). Contractile performance was also evaluated in 5 hypertensive LVH patients and 5 matched normal control subjects (magnetic resonance [MR] substudy). Myocardial FA utilization (MFAU) and myocardial FA oxidation (MFAO) were assessed by positron emission tomography by use of 1-carbon-11 palmitate. Myocardial contractile function (strain and stress) was determined by cardiac MR imaging with tissue tagging and calibrated arterial pressure traces; myocardial external minute work and efficiency were derived. In the primary cohort decreased MFAO was predictive of increased LV mass (model r(2) = 0.61, P = .03). In the MR substudy decreased MFAO (corrected for myocardial oxygen consumption [MVO(2)]) in the hypertensive LVH group compared with the normal group (MFAU/MVO(2), 26 +/- 5 vs 37 +/- 8; MFAO/MVO(2), 24 +/- 6 vs 35 +/- 7; both P = .03) was paralleled by decreased myocardial external minute work (0.13 +/- 0.03 J x g(-1) x min(-1) vs 0.17 +/- 0.04 J x g(-1) x min(-1), P = .07) and decreased myocardial efficiency (5.2% +/- 1.4% vs 7.1% +/- 1.0%, P = .03). CONCLUSIONS: Abnormalities in myocardial FA metabolism are apparent in hypertensive LVH, and these abnormalities may be responsible, at least in part, for a reduction in myocardial efficiency.
BACKGROUND:Hypertension-induced left ventricular hypertrophy (LVH) is associated with an increased risk of cardiovascular morbidity and death by mechanisms not well characterized. METHODS AND RESULTS:Myocardial fatty acid (FA) metabolism and left ventricular (LV) mass were evaluated in 13 patients with hypertensive LVH with normal LV ejection fraction and 42 normal control subjects (primary cohort). Contractile performance was also evaluated in 5 hypertensive LVHpatients and 5 matched normal control subjects (magnetic resonance [MR] substudy). Myocardial FA utilization (MFAU) and myocardial FA oxidation (MFAO) were assessed by positron emission tomography by use of 1-carbon-11 palmitate. Myocardial contractile function (strain and stress) was determined by cardiac MR imaging with tissue tagging and calibrated arterial pressure traces; myocardial external minute work and efficiency were derived. In the primary cohort decreased MFAO was predictive of increased LV mass (model r(2) = 0.61, P = .03). In the MR substudy decreased MFAO (corrected for myocardial oxygen consumption [MVO(2)]) in the hypertensive LVH group compared with the normal group (MFAU/MVO(2), 26 +/- 5 vs 37 +/- 8; MFAO/MVO(2), 24 +/- 6 vs 35 +/- 7; both P = .03) was paralleled by decreased myocardial external minute work (0.13 +/- 0.03 J x g(-1) x min(-1) vs 0.17 +/- 0.04 J x g(-1) x min(-1), P = .07) and decreased myocardial efficiency (5.2% +/- 1.4% vs 7.1% +/- 1.0%, P = .03). CONCLUSIONS: Abnormalities in myocardial FA metabolism are apparent in hypertensive LVH, and these abnormalities may be responsible, at least in part, for a reduction in myocardial efficiency.
Authors: H Laine; C Katoh; M Luotolahti; H Yki-Järvinen; I Kantola; A Jula; T O Takala; U Ruotsalainen; H Iida; M Haaparanta; P Nuutila; J Knuuti Journal: Circulation Date: 1999-12-14 Impact factor: 29.690
Authors: F F Ungacta; V G Dávila-Román; M J Moulton; B P Cupps; P Moustakidis; D S Fishman; R Actis; B A Szabo; D Li; N T Kouchoukos; M K Pasque Journal: Ann Thorac Surg Date: 1998-04 Impact factor: 4.330
Authors: N B Schiller; P M Shah; M Crawford; A DeMaria; R Devereux; H Feigenbaum; H Gutgesell; N Reichek; D Sahn; I Schnittger Journal: J Am Soc Echocardiogr Date: 1989 Sep-Oct Impact factor: 5.251
Authors: H Nakayama; T Morozumi; S Nanto; T Shimonagata; T Ohara; Y Takano; J Kotani; T Watanabe; M Fujita; M Nishio; H Kusuoka; M Hori; S Nagata Journal: Jpn Circ J Date: 2001-09
Authors: C Kurata; K Tawarahara; T Taguchi; S Aoshima; A Kobayashi; N Yamazaki; H Kawai; M Kaneko Journal: J Nucl Med Date: 1992-01 Impact factor: 10.057
Authors: Lisa de las Fuentes; Giovanni de Simone; Donna K Arnett; Víctor G Dávila-Román Journal: Endocr Metab Immune Disord Drug Targets Date: 2010-06 Impact factor: 2.895
Authors: Yinlin Li; Tao Huang; Xinyue Zhang; Min Zhong; Natalie N Walker; Jiang He; Stuart S Berr; Susanna R Keller; Bijoy K Kundu Journal: Mol Imaging Date: 2015 Impact factor: 4.488
Authors: Andrew M Hernandez; Jennifer S Huber; Stephanie T Murphy; Mustafa Janabi; Gengsheng L Zeng; Kathleen M Brennan; James P O'Neil; Youngho Seo; Grant T Gullberg Journal: J Nucl Med Date: 2013-10-03 Impact factor: 10.057
Authors: Yasmin S Hamirani; Bijoy K Kundu; Min Zhong; Andrew McBride; Yinlin Li; Giovanni E Davogustto; Heinrich Taegtmeyer; Jamieson M Bourque Journal: Cardiology Date: 2015-11-24 Impact factor: 1.869